fda compounding semaglutide warning september 2025 Beyond the Headlines: Letters to GLP-1 Compounders Semaglutide for weight loss |

About 9-10% of participants stopped treatment because of side-effects mainly gastrointestinal issues compared with 4-5% in the semaglutide groups

GLP-1 receptor agonists have become a cornerstone in the treatment of type 2 diabetes, offering several advantages over traditional therapies: Blood sugar control: GLP-1s effectively lower blood glucose levels, with an average reduction in hemoglobin A1c (HA1C) of about 1% compared to control groups

Semaglutide is suitable for individuals with a BMI of 27 or higher, especially those with weight-related health conditions such as type 2 diabetes, hypertension, or high cholesterol

A recent meta-analysis by Apperloo and colleagues provides evidence that addition of an SGLT2 inhibitor to a GLP-1 receptor agonist effectively reduces cardiovascular events and progression of chronic kidney disease in high-risk type 2 diabetes patients

However, you may reduce the risk, severity and frequency of these side effects by gradually increasing your weekly semaglutide dosage